Quick Answer
NextCure, Inc. reported Stockholders Equity of $34.94 million for the year ending 2025.
- NextCure, Inc. showed a decrease of -46.6% in Stockholders Equity from 2024 to 2025.
- This data is from NextCure, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$29.39 million | Q2 2018: -$34.59 million | Q3 2018: -$40.21 million | Q1 2019: -$52.71 million | Q2 2019: $178.60 million | Q3 2019: $170.65 million | Q1 2020: $331.76 million | Q2 2020: $321.92 million | Q3 2020: $307.34 million | Q1 2021: $279.16 million | Q2 2021: $263.60 million | Q3 2021: $248.23 million | Q1 2022: $213.94 million | Q2 2022: $198.20 million | Q3 2022: $181.54 million | Q1 2023: $154.20 million | Q2 2023: $138.43 million | Q3 2023: $126.45 million | Q1 2024: $99.05 million | Q2 2024: $85.44 million | Q3 2024: $75.59 million | Q1 2025: $55.86 million | Q2 2025: $29.65 million | Q3 2025: $23.65 million.
- Over the full 9 years of available data (2017 to 2025), NextCure, Inc.'s Stockholders Equity has grown by 243.1%.
- Historical annual values: Fiscal year 2025: $34.94 million | Fiscal year 2024: $65.47 million | Fiscal year 2023: $114.42 million | Fiscal year 2022: $167.53 million | Fiscal year 2021: $233.39 million | Fiscal year 2020: $293.72 million | Fiscal year 2019: $321.48 million | Fiscal year 2018: -$46.94 million | Fiscal year 2017: -$24.41 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: